Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/17/2024 | $48.00 | Buy | Stifel |
| 12/18/2023 | $60.00 → $58.00 | Buy | H.C. Wainwright |
| 11/20/2023 | $37.00 | Overweight | JP Morgan |
| 11/13/2023 | $60.00 | Overweight | Morgan Stanley |
| 10/24/2023 | $50.00 | Overweight | Cantor Fitzgerald |
| 10/17/2023 | $62.00 | Outperform | Evercore ISI |
| 9/20/2023 | $70.00 | Mkt Outperform | JMP Securities |
| 9/1/2022 | $38.00 | Buy | Citigroup |
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). The expanded label includes use in PFIC patients 12 months and older as well as the higher concentration formulation of LIVMARLI evaluated in the MARCH Phase 3 study.
- Form 13G
HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $66 price target.
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
10-Q - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
Stifel initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $48.00
H.C. Wainwright reiterated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $58.00 from $60.00 previously
JP Morgan resumed coverage of Mirum Pharmaceuticals with a rating of Overweight and set a new price target of $37.00
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report third quarter 2024 financial results on November 12, 2024. Mirum will also host a conference call to discuss the third quarter 2024 financial results and recent corporate progress. Conference call details: Tuesday, November 12, 2024 8:30 a.m. ET / 5:30 a.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 749358 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company
Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies LIVMARLI for treatment of PFIC granted marketing authorization in Europe Initiating LIVMARLI EXPAND study for pruritus in rare cholestatic conditions Conference call to provide business updates today, August 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for second quarter 2024 and provided a business update. "The second quarter was marked by significant achievements across both our commercial medicines and development p
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report second quarter 2024 financial results on August 7, 2024. Mirum will also host a conference call to discuss the second quarter 2024 financial results and recent corporate progress. Conference call details: Wednesday, August 7, 2024 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: +1 833 470 1428 International: +1 404 975 4839 Passcode: 771307 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedica
SC 13G - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: Stifel 2024 Healthcare Conference on Tuesday, November 19th Company presentation - Tuesday, November 19th starting at 10:20 a.m. ET 7th Annual Evercore HealthCONx Conference on Tuesday, December 3rd Company presentation - Tuesday, December 3rd starting at 2:10 p.m. ET Citi's 2024 Global Healthcare Conference on Wednesday, December 4th Visit the Investors and Media section of Mir
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report third quarter 2024 financial results on November 12, 2024. Mirum will also host a conference call to discuss the third quarter 2024 financial results and recent corporate progress. Conference call details: Tuesday, November 12, 2024 8:30 a.m. ET / 5:30 a.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 749358 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting taking place November 6-9, 2024, in Hollywood, Florida. Data highlighting clinical benefit and real-world evidence for patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC), treated with LIVMARLI® (maralixibat) oral solution, will be presented during the meeting. Highlighted below are the titles that have been accepted for presentation during the meeting. The abstracts are available via the NASPGHAN Program Book. Full analyses will be available following their p
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
Se NodThera Ltd ("NodThera" or the "Company") NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc., FMH as Chief Medical Officer (CMO), with effect from today. With more than 20 years of experience across global large pharma, biotech and academic medicine, Dr. Jaecklin is an accomplished late-stage drug development leader. He brings deep expertise across multiple therapy areas, including neuroscience and inflammation, with a strong track reco
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that in conjunction with the recent appointment of Joanne Quan, MD as Chief Medical Officer, the Compensation Committee of Mirum's Board of Directors approved an inducement grant of non-qualified stock options to purchase 75,000 shares of common stock and 37,500 restricted stock units ("RSUs") under Mirum's 2020 Inducement Plan. The Compensation Committee approved the awards as an inducement material to Dr. Quan's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $26.72 per share, Mirum's closing trading price on January 16, 2024, and will vest over four years, wi